studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 429A
Disclosures:
The following authors have nothing to disclose: Andrea Casadei Gardini, Giorgia
Marisi, Paola Ulivi, Luca Faloppi, Emanuela Scarpi, Mario Scartozzi, Francesco
G. Foschi, Massimo Iavarone, Gianfranco Lauletta, Jody Corbelli, Elena
Tenti, Floriana Facchetti, Cristina Della Corte, Stefano Tamberi, Oriana Nanni,
Stefanu Cascinu, Dino Amadori, Giovanni Luca Frassineti
other liver diseases (4%). There was no significant difference in
frequency of miR-26a loss in patients with advanced versus less
advanced HCC regardless of treatment (79% vs 74% in resection
cases and 50% vs 60% in transplanted cases). Conclusions:
Loss of miR-26a in the tumor tissue relative to surrounding
liver tissue is a common phenomenon in HCC regardless the
etiology or prior liver directed therapy but it was not associated
with an aggressive tumor phenotype. More studies are needed
to understand the biological significance of this observation.
Disclosures:
Naga P. Chalasani - Consulting: Abbvie, Lilly, Celgene, Tobira, NuSirt, Takeda,
Merck/Anthem, Salix; Grant/Research Support: Intercept, Gilead, Galectin
The following authors have nothing to disclose: Sarah C. Nabinger, Samer Gawrieh,
Maaz B. Badshah, Sandra K. Althouse, Smitha Marri, Sangbin Lee, Smiti S.
Sahu, Susan Perkins, Romil Saxena, Janaiah Kota
436
MicroRNA-26 expression is significantly lower in hepatocellular
carcinoma relative to surrounding liver tissue
in humans with chronic liver disease
Sarah C. Nabinger 1 , Samer Gawrieh 3 , Maaz B. Badshah 3 , Sandra
K. Althouse 2 , Smitha Marri 3 , Sangbin Lee 1 , Smiti S. Sahu 1 ,
Susan Perkins 2 , Romil Saxena 4 , Naga P. Chalasani 3 , Janaiah
Kota 1 ; 1 Medical and Molecular Genetics, Indiana University
School of Medicine, Indianapolis, IN; 2 Biostatistics, Indiana University
School of Medicine, Indianapolis, IN; 3 of Gastroenterology/
Hepatology, Indiana University School of Medicine, Indianapolis,
IN; 4 Pathology and Laboratory Medicine, Indiana University
School of Medicine, Indianapolis, IN
Background & Aim: Hepatocellular Carcinoma (HCC) is the
third leading cause of cancer-related deaths worldwide. We
have previously shown that loss of microRNA-26a (miR-26)
is common in murine HCC and systemic delivery of miR-26a
suppressed liver tumor development in a mouse model of HCC.
In this study, we investigated if miR-26 loss occurs with HCC
in a large cohort of patients with underlying liver disease and
assessed its correlation with advanced tumor features. Methods:
We identified 136 paired tumor and normal adjacent
liver tissues from HCC patients undergoing tumor resection
(n=87) or liver transplantation (n=49) at Indiana University
Medical Center. Total RNA was isolated from formalin fixed
paraffin embedded tumor and normal adjacent liver samples,
and subjected to quantitative PCR analysis to estimate miR-26a
levels in these patients. The prevalence of miR-26 loss, defined
by a relative fold change